Editor’s pick: Vilya Therapeutics

editor’s-pick:-vilya-therapeutics

Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Vilya Therapeutics is designing macrocycle drug candidates.

References

Author information

Authors and Affiliations

  1. Philadelphia, PA, USA

    Michael Eisenstein

Authors

  1. Michael Eisenstein

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eisenstein, M. Editor’s pick: Vilya Therapeutics. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02782-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41587-025-02782-x